|
|
|
|
| LEADER |
00000cam a2200000 i 4500 |
| 001 |
on1228650104 |
| 003 |
OCoLC |
| 005 |
20241006213017.0 |
| 006 |
m o d |
| 007 |
cr ||||||||||| |
| 008 |
201207t20212021si a o 000 0 eng d |
| 040 |
|
|
|a SFB
|b eng
|e rda
|e pn
|c SFB
|d OCLCO
|d EBLCP
|d OCLCF
|d GW5XE
|d YDX
|d UPM
|d BDX
|d OCLCO
|d DCT
|d N$T
|d OCL
|d DKU
|d OCLCO
|d IBI
|d OCLCO
|d OCLCQ
|d CASUM
|d OCLCO
|d OCLCL
|
| 019 |
|
|
|a 1226532208
|a 1226582678
|a 1228843477
|a 1229918959
|a 1238201111
|a 1244634797
|a 1250576628
|
| 020 |
|
|
|a 9789811584237
|q (electronic book)
|
| 020 |
|
|
|a 9811584230
|q (electronic book)
|
| 020 |
|
|
|z 9789811584220
|q (hardcover)
|
| 020 |
|
|
|z 9811584222
|q (hardcover)
|
| 024 |
7 |
|
|a 10.1007/978-981-15-8423-7
|2 doi
|
| 035 |
|
|
|a (OCoLC)1228650104
|z (OCoLC)1226532208
|z (OCoLC)1226582678
|z (OCoLC)1228843477
|z (OCoLC)1229918959
|z (OCoLC)1238201111
|z (OCoLC)1244634797
|z (OCoLC)1250576628
|
| 037 |
|
|
|b Springer
|
| 050 |
|
4 |
|a RC270.3.T65
|b A665 2021eb
|
| 072 |
|
7 |
|a MJCL
|2 bicssc
|
| 072 |
|
7 |
|a MED062000
|2 bisacsh
|
| 072 |
|
7 |
|a MJCL
|2 thema
|
| 049 |
|
|
|a HCDD
|
| 245 |
0 |
0 |
|a Applications of FDG PET in oncology :
|b best clinical practice /
|c Hirofumi Fujii, Hiroyuki Nakamura, Seiei Yasuda, editors.
|
| 264 |
|
1 |
|a Singapore :
|b Springer,
|c [2021]
|
| 264 |
|
4 |
|c ©2021
|
| 300 |
|
|
|a 1 online resource (vii, 147 pages) :
|b illustrations (chiefly color)
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 347 |
|
|
|a text file
|
| 347 |
|
|
|b PDF
|
| 520 |
|
|
|a This book provides up-to-date guidance on the use of FDG PET to assess the biological activity and treatment response of a wide range of malignancies, including, for example, lung cancer, breast cancer, head and neck cancer, gastrointestinal cancer, and malignant lymphoma. In the era of precision medicine, numerous new anticancer agents, such as molecular targeted agents and immune checkpoint inhibitors, have been developed to improve outcomes in cancer patients. FDG PET plays a key role in evaluating the effects of these novel treatments because it can detect changes in the metabolic activity of tumors before any reduction in their size is visible on other imaging modalities. Accordingly, FDG PET is of prognostic as well as diagnostic value, and allows prompt changes in patient management. The book is written by expert clinicians from Japan, where the universal public health insurance system ensures that FDG PET is widely used in routine oncological practice and cancer screening. It represents an unrivaled and comprehensive resource that will be of value for all healthcare professionals in the field of clinical oncology.
|
| 505 |
0 |
|
|a 1 Overview.-2 Lung cancer.-3 Breast cancer -- 4 Head and neck cancer.-5 Gastrointestinal cancer including GIST -- 6 Pancreatic cancer -- 7 Urological cancer -- 8 Malignant bone and soft tissue tumors -- 9 Skin cancer including malignant melanoma -- 10 Malignant lymphoma.
|
| 588 |
0 |
|
|a Online resource; title from PDF title page (SpringerLink, viewed February 16, 2021).
|
| 650 |
|
0 |
|a Tomography, Emission.
|
| 650 |
|
0 |
|a Cancer
|x Tomography.
|
| 650 |
|
0 |
|a Oncology.
|
| 650 |
|
0 |
|a Radiology.
|
| 650 |
|
0 |
|a Cancer
|x Research.
|
| 650 |
|
7 |
|a radiology.
|2 aat
|
| 650 |
|
7 |
|a Tomography, Emission
|2 fast
|
| 650 |
|
7 |
|a Cancer
|x Tomography
|2 fast
|
| 650 |
|
7 |
|a Cancer
|x Research
|2 fast
|
| 650 |
|
7 |
|a Oncology
|2 fast
|
| 650 |
|
7 |
|a Radiology
|2 fast
|
| 700 |
1 |
|
|a Fujii, H.
|q (Hirofumi),
|e editor.
|1 https://id.oclc.org/worldcat/entity/E39PCjDHmWWVhkcDXfbt3mhVbq
|
| 700 |
1 |
|
|a Nakamura, Hiroyuki,
|e editor.
|
| 700 |
1 |
|
|a Yasuda, Seiei,
|e editor.
|
| 758 |
|
|
|i has work:
|a Applications of FDG PET in oncology (Text)
|1 https://id.oclc.org/worldcat/entity/E39PCFMFWXV7bKHBwRvY4GTwfm
|4 https://id.oclc.org/worldcat/ontology/hasWork
|
| 776 |
0 |
8 |
|i Print version:
|z 9811584222
|z 9789811584220
|
| 856 |
4 |
0 |
|u https://holycross.idm.oclc.org/login?auth=cas&url=https://link.springer.com/10.1007/978-981-15-8423-7
|y Click for online access
|
| 903 |
|
|
|a SPRING-MED2021
|
| 994 |
|
|
|a 92
|b HCD
|